Viewing nowCombinationSitagliptin Metformin Extended Release Tablet 50/1000 mg
Sitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
DaeHwa Pharmaceutical Co., Ltd.

MFDS item code 202300578 · Approved 2023.02.16 · Insurance code 645605840
Improves blood glucose control in patients with type 2 diabetes mellitus
This medication helps improve blood glucose control in patients with type 2 diabetes when used in conjunction with diet and exercise. The combination of sitagliptin and metformin effectively lowers blood glucose levels, making it useful for diabetes management. It can improve blood glucose control and reduce the risk of complications.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily with a meal, preferably in the evening, and increase the dose gradually. To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take 1 tablet of this medicine 100/1000 mg extended-release tablet once daily. Patients taking this medicine 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently treated with metformin: For patients who have not previously received antidiabetic drug therapy and whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control is not achieved with the initial dose, the dose may be gradually increased up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine. 2. Patients receiving metformin: - The recommended initial total daily dose of this medicine for patients whose blood glucose is not adequately controlled with metformin monotherapy is sitagliptin 100 mg and the current metformin dose. - Patients switching to this medicine from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release metformin at a current dose of 850 mg or 1000 mg twice daily may start this medicine at a dose of 2 tablets of 50/1000 mg extended-release tablets once daily. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. Increase the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. When used concomitantly with a sulfonylurea or insulin, reduction of the sulfonylurea or insulin dose may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately.
This medication contains two ingredients: sitagliptin and metformin. Firstly, the sitagliptin component can cause rare but serious allergic reactions. These reactions can include hives, angioedema, anaphylaxis, or severe skin conditions with skin peeling. If any abnormal symptoms appear within three months after taking the medication, the drug should be immediately discontinued and a doctor should be consulted. Additionally, sitagliptin carries a risk of acute pancreatitis, which involves inflammation of the pancreas. If symptoms of pancreatitis such as abdominal pain or vomiting occur during treatment, the medication must be stopped immediately and medical personnel should be informed. Secondly, the metformin component can cause a rare side effect called lactic acidosis, which is a dangerous condition characterized by abnormal accumulation of lactic acid in the blood, with symptoms including muscle pain, breathing difficulties, and fatigue. Immediate treatment is necessary if these symptoms occur. This medication should not be administered to patients with moderate to severe renal impairment, acute heart failure, severe infections, dehydration, acute myocardial infarction, patients scheduled for radiographic contrast examinations, type 1 diabetes patients, or women who are pregnant or breastfeeding. Particularly, if a patient is to undergo a contrast procedure, this medication should be paused for a certain period before and after the examination to reduce kidney burden, and it should only be resumed after confirming normal kidney function. Furthermore, patients with irregular eating habits, excessive exercise, those taking certain medications, and those allergic to the ingredient Yellow No. 4 (tartrazine) should be cautious when using this medication. During treatment, abnormal symptoms such as gastrointestinal disturbances, hypoglycemia, and allergic reactions may occur, thus careful observation is necessary, and immediate consultation with medical personnel is required if any abnormal symptoms appear.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to avoid exposure to air or moisture, and it is important to maintain a temperature between 1 degree and 30 degrees Celsius at room temperature. Proper storage will help maintain the medication's effectiveness and prevent degradation.
Bright green oval extended-release film-coated tablets
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
DaeHwa Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.